<DOC>
	<DOCNO>NCT01881789</DOCNO>
	<brief_summary>Phase 1b : - To establish maximum tolerate dose ( MTD ) oprozomib dexamethasone administer combination lenalidomide oral cyclophosphamide - To evaluate safety tolerability oprozomib dexamethasone administer combination lenalidomide oral cyclophosphamide Phase 2 : - To estimate overall response rate ( ORR ) complete response rate ( CRR ) - To evaluate safety tolerability oprozomib dexamethasone administer combination lenalidomide oral cyclophosphamide Secondary Objectives : - To evaluate population pharmacokinetic ( PK ) parameter estimate oprozomib variability estimate administer combination dexamethasone lenalidomide oral cyclophosphamide - To estimate duration response ( DOR ) - To estimate progression-free survival ( PFS )</brief_summary>
	<brief_title>Study Oprozomib Dexamethasone , Combination With Lenalidomide Oral Cyclophosphamide Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Key Newly diagnose , symptomatic multiple myeloma patient treatment indicate per NCCN guideline , hematopoietic stem cell transplant plan schedule study consider ineligible hematopoietic stem cell transplant , measurable disease Creatinine clearance â‰¥ 50 mL/min ( measure calculate use Cockcroft Gault formula ) Key Any prior systemic antimyeloma therapy except oral steroid ( dexamethasone total dose 160 mg equivalent within 14 day prior first dose study treatment ) . Use topical inhale steroid acceptable Radiation therapy within 2 week prior first dose Major surgery within 3 week prior first dose Active infection require systemic antibiotic , antiviral , antifungal within 2 week prior first dose Clinical significant gastrointestinal bleed 6 month prior Cycle 1 Day 1 ( C1D1 ) first dose Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose Other malignancy within past 3 year except consider cured surgical resection include case : exception adequately treat basal squamous cell carcinoma skin , squamous cell skin cancer , thyroid cancer , carcinoma situ breast cervix , carcinoma situ breast , prostate cancer Gleason Score 6 less stable prostate specific antigen levels. , cancer consider cure surgical resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>proteasome inhibitor</keyword>
	<keyword>oprozomib</keyword>
	<keyword>orpozomib tablet</keyword>
</DOC>